Centene Corporation (NYSE:CNC – Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders purchased 22,328 put options on the stock. This is an increase of 67% compared to the average volume of 13,355 put options.
Centene Price Performance
NYSE CNC opened at $35.91 on Thursday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.10 and a current ratio of 1.10. The business’s fifty day moving average is $43.09 and its 200 day moving average is $38.32. The company has a market capitalization of $17.66 billion, a PE ratio of -2.64, a price-to-earnings-growth ratio of 0.81 and a beta of 0.48. Centene has a fifty-two week low of $25.08 and a fifty-two week high of $66.03.
Centene (NYSE:CNC – Get Free Report) last posted its quarterly earnings data on Friday, February 6th. The company reported ($1.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.03. Centene had a positive return on equity of 4.25% and a negative net margin of 3.43%.The firm had revenue of $49.73 billion for the quarter, compared to analysts’ expectations of $48.41 billion. During the same period in the previous year, the firm earned $0.80 EPS. The business’s quarterly revenue was up 21.9% on a year-over-year basis. Centene has set its FY 2026 guidance at 3.000-3.000 EPS. Sell-side analysts predict that Centene will post 6.86 earnings per share for the current year.
Institutional Investors Weigh In On Centene
Key Headlines Impacting Centene
Here are the key news stories impacting Centene this week:
- Positive Sentiment: Superior HealthPlan (a Centene unit) named a Rio Grande Valley provider a Foster Care Center of Excellence — a local operating win that supports managed‑care positioning in Texas. Superior HealthPlan Names Cute Pediatrics as First Rio Grande Valley Provider to Earn Foster Care Distinction
- Positive Sentiment: Company update: Centene reaffirmed its 2026 outlook and redeemed certain debt notes — signaling liquidity/commitment to guidance despite near‑term headwinds. Centene Reaffirms 2026 Outlook and Redeems Debt Notes
- Neutral Sentiment: Management presentation/transcript from Barclays conference is available — useful for detail on guidance and membership trends but did not offset market concern. Centene Corporation (CNC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- Neutral Sentiment: Industry context: analysts note HMO names face cost pressure, nursing shortages and policy risk — structural headwinds that increase sensitivity to ACA enrollment swings. 4 HMO Stocks to Watch Despite Escalating Costs, Nursing Shortage
- Negative Sentiment: CEO warning of a steep ACA membership decline: management said individual-market enrollment may fall to ~3.5M from ~5.5M — a dramatic reduction that directly cuts revenue and hurts margins, and was cited as the primary catalyst for the selloff. Centene (CNC) Stock Plunges 14% as CEO Warns of Massive ACA Enrollment Decline
- Negative Sentiment: News and market reactions: multiple outlets report shares falling after executives flagged steeper ACA membership losses; Mizuho and other analysts lowered targets/expressed caution. Centene shares fall as health insurer sees steeper drop in Obamacare memberships
- Negative Sentiment: Broader coverage: stories framing the “slow death” of enhanced ACA subsidies and plunging enrollment directly link the policy shift to Centene’s weakness. Obamacare’s Slow Death Is Debilitating Centene Stock
- Negative Sentiment: Market signals: unusually high put‑option volume and elevated trading volume show short/bear positioning and higher conviction among downside traders, amplifying price moves.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $41.00 target price on shares of Centene in a research report on Monday, February 9th. Mizuho set a $41.00 price target on Centene and gave the stock a “neutral” rating in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Centene in a report on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft increased their target price on Centene from $32.00 to $39.00 and gave the company a “hold” rating in a report on Tuesday, February 10th. Finally, Wall Street Zen downgraded Centene from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. Three equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, Centene presently has a consensus rating of “Hold” and an average target price of $42.06.
Check Out Our Latest Report on Centene
About Centene
Centene Corporation (NYSE: CNC) is a diversified, multi-national healthcare enterprise that specializes in providing services to government-sponsored and national health programs. The company primarily acts as a managed care organization, delivering healthcare coverage and administering benefits for Medicaid, the Children’s Health Insurance Program (CHIP), Medicare Advantage, and individual marketplace plans. Centene also contracts with federal and state agencies to manage specialty care programs and community-based services for vulnerable populations.
Centene’s offerings extend beyond traditional insurance to include a range of specialty and support services.
Read More
- Five stocks we like better than Centene
- The Next Commodity Crunch (bigger than oil?)
- What a Former CIA Agent Knows About the Coming Collapse
- The gold chart Wall Street is terrified of…
- I tried out Elon Musk’s new AI tech — it floored me
- “I just bought 10,000 shares of a $5 stock…”
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.
